Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance

Bristol-Myers Squibb CoTrade
Invesco DB Commodity Index Tracking FundTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Invesco DB Commodity Index Tracking Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while Invesco DB Commodity Index Tracking Fund trades at $29.97. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals.

BMYDBC
Market Cap
$132.45B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$65.89$31.69
52-Week Low
$42.60$21.62
Enterprise Value
$166.44B
Dividend Yield
3.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.

BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.

Invesco DB Commodity Index Tracking Fund

DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.

The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.

Returns comparison

Trailing returns across standard periods

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Invesco DB Commodity Index Tracking Fund

DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.

Read more on DBC